Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

April 11, 2026Pathologica0 citationsOpen Access

Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers

APAnello Marcello PomaUniversity of Pisa ACAlessandra CeliUniversity of Pisa VAVittorio AprileUniversity of Pisa

Key Points

The study aims to identify specific ancillary biomarkers that can distinguish thymic carcinoma from type B3 thymoma.
Evaluated the expression of markers CD5 and CD117 in thymic carcinoma and type B3 thymoma.
Assessed additional markers including BAP1, MTAP, and CDKN2A for their diagnostic value.
Analyzed cases that tested negative for CD5 and CD117.
CD5 and CD117 were identified as the most reliable markers for thymic carcinoma.
The additional markers BAP1 loss, MTAP loss, and CDKN2A deletion may aid in diagnosing certain cases.
Rare cases of type B3 thymoma exhibited alterations similar to those seen in thymic carcinoma.

Abstract

CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.

问 AI

Like

Bookmark

Share

View Full Paper

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Poma et al. (Sun,) studied this question.

synapsesocial.com/papers/69d9e50778050d08c1b7543c https://doi.org/https://doi.org/10.32074/1591-951x-1652

Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers | Synapse